Preferred test to follow-up presumptive results. For general screening, Buprenorphine, Urine Screen with Reflex to Quantitation (2012273) is preferred.
Quantitative Liquid Chromatography-Tandem Mass Spectrometry
Transfer 2 mL urine with no additives or preservatives to an ARUP Standard Transport Tube. (Min: 1 mL)
Ambient: 1 week; Refrigerated: 1 month; Frozen: 3 years (Avoid repeated freeze/thaw cycles)
Effective August 17, 2015
|Drugs Covered||Cutoff Concentrations|
|Buprenorphine glucuronide||5 ng/mL|
|Norbuprenorphine glucuronide||5 ng/mL|
Methodology: Quantitative Liquid Chromatography-Tandem Mass Spectrometry
Buprenorphine 2 ng/mL
Norbuprenorphine 2 ng/mL
Buprenorphine glucuronide 5 ng/mL
Norbuprenorphine glucuronide 5 ng/mL
Naloxone 100 ng/mL
For medical purposes only; not valid for forensic use.
The presence of metabolite(s) without parent drug is common and may indicate use of parent drug during the prior week. Naloxone is included to detect the addition of a naloxone-containing drug directly into the urine.
The absence of expected drug(s) and/or drug metabolite(s) may indicate non-compliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, diluted/adulterated urine, or limitations of testing. The concentration value must be greater than or equal to the cutoff to be reported as positive. Interpretive questions should be directed to the laboratory.
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
Laboratory Developed Test (LDT)
80348 (Alt code: G0480)
|Component Test Code*||Component Chart Name||LOINC|
|2002750||Norbuprenorphine, Urn, Quant||49753-7|
|2002752||Buprenorphine, Urn, Quant||3415-7|
|2005863||Naloxone, Urn, Quant||77207-9|
|2010093||Buprenorphine Gluc, Urn, Quant|
|2010094||Norbuprenorphine Gluc, Urn, Quant||49751-1|
- Medication Adherence
- Opioids use disorders
- Pain Management